Clinical Trial Update: Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating short course peginterferon alfa-2b plus ribavirin in chronic hepatitis C genotype 4 patients who achieved rapid virological response at…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 4 | Status: TERMINATED | Results posted: 2016-02-23